Ipamorelin (10 mg) – Research Peptide

Ipamorelin is a highly selective growth hormone secretagogue (GHS) and agonist of the ghrelin receptor (GHSR-1a).
Its high specificity, minimal off-target hormonal activation, and clean signaling profile make it widely used in experimental research involving GH dynamics, cellular regeneration, musculoskeletal biology, gastrointestinal function, and neuroendocrine studies.

Specifications

Synonyms: Ipamorelin, NNC-26-0161
Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: 711.86 Da
Class: Growth hormone secretagogue / GHSR-1a agonist
Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Mechanism of Action

Ipamorelin works by selectively stimulating GHSR-1a, triggering GH release through:

1. Activation of hypothalamic GH-releasing pathways

2. Inhibition of somatostatin release, the primary GH suppressant

3. Stimulation of pituitary somatotrophs, increasing pulsatile GH secretion

4. Minimal impact on ACTH, cortisol, or prolactin, unlike many other GHRPs

Selective GHSR-1a Agonism

Comparative studies show Ipamorelin has:

• Lower corticotropin release vs. GHRP-6 and hexarelin

• Minimal effect on aldosterone, prolactin, luteinizing hormone

• A clean GH-specific profile suitable for mechanistic research

(Raun et al., Novo Nordisk Studies)

Ipamorelin and Growth Hormone Signaling

Ipamorelin increases circulating GH, which activates:

• JAK2 → STAT5

• MAPK/ERK

• PI3K → Akt → mTOR pathways

These pathways modulate:

• Muscle protein synthesis

• Cell growth

• Tissue regeneration

• Fat metabolism

1. Muscle Biology

GH-driven IGF-1 production affects:

• Satellite cell activation

• Muscle fiber hypertrophy

• Recovery after overload or injury

Animal studies show GH secretagogues can enhance collagen turnover and muscle anabolism.

2. Bone & Connective Tissue

GH/IGF-1 axis research shows:

• Increased osteoblast proliferation

• Enhanced bone matrix deposition

• Support for tendon/ligament remodeling in injury models

3. Anti-Catabolic Effects

In preclinical models, GH secretagogues:

• Attenuated muscle wasting

• Reduced proteolysis in catabolic states

• Improved nitrogen balance

Ipamorelin in Metabolic Research

GH signaling significantly affects metabolic homeostasis. Research models demonstrate:

Fat Metabolism

GH increases:

• Lipolysis

• Fatty-acid mobilization

• β-oxidation

Glucose Regulation

Although GH can temporarily raise glucose, studies indicate ipamorelin itself does not directly impair glucose tolerance.

Neuroendocrine and CNS Studies

The ghrelin receptor (GHSR-1a) is widely expressed in:

• Hypothalamus

• Pituitary

• Reward centers

• Vagal afferents

Potential research effects include:

• Appetite modulation

• Neuroprotection

• Stress-axis regulation

Rodent studies show GHSR activation may support neuronal survival and synaptic plasticity.

Gastrointestinal Motility

Ghrelin mimetics (including ipamorelin) stimulate:

• Gastric emptying

• GI motility

• Vagal pathways

This is relevant in research on postoperative ileus and motility disorders.

Comparative Selectivity vs. Other GHRPs

Ipamorelin is the cleanest experimental GHRP with lowest hormonal spillover.

Other Experimental Applications

Tissue Regeneration

GH/IGF-1 signaling is implicated in:

• Wound healing

• Tendon recovery

• Postoperative muscle retention

Aging Research

GH dynamics decline with age; models use ipamorelin to study:

• Sarcopenia

• Bone loss

• Declining GH pulse amplitude

Sleep & Circadian Rhythm

GH is primarily released during sleep; secretagogues enable study of GH–sleep interactions.

Research Use Only – Important Notice

This Ipamorelin 10 mg product is supplied exclusively for laboratory research.

• Not for human or veterinary use

• Not for diagnostic, therapeutic, or cosmetic purposes

• Intended for in vitro and controlled animal-model research only

• All descriptions summarize preclinical findings

• Not to be interpreted as medical advice

References

1. Raun K et al. Ipamorelin, a novel GH secretagogue: selectivity profile and endocrine effects. European Journal of Endocrinology.
   https://doi.org/10.1530/eje.0.1390445

2. Ghigo E et al. Growth hormone-releasing peptides and GH secretagogues: mechanisms and clinical applications. Endocrine Reviews.
   https://doi.org/10.1210/edrv.18.4.0306

3. van der Lely AJ et al. Ghrelin and its receptor in GH regulation. Nature Clinical Practice Endocrinology & Metabolism.
   https://doi.org/10.1038/ncpendmet0197

4. Zizzari P et al. Central effects of ghrelin on appetite and pituitary hormones. Neuroscience Letters.
   https://doi.org/10.1016/S0304-3940(03)00944-8

5. Granado M et al. Ghrelin’s impact on bone physiology. Growth Hormone & IGF Research.
   https://doi.org/10.1016/j.ghir.2005.12.002

6. Tsolakis AV et al. Ghrelin receptor distribution and implications for neuroendocrine function. Regulatory Peptides.
   https://doi.org/10.1016/j.regpep.2004.11.006

7. Chance WT et al. GHSR agonists improve gastric motility in postoperative models. Surgical Endoscopy.
   https://doi.org/10.1007/s00464-012-2585-4